Advanced Proteome Therapeutics Corporation (APC.V)
| Previous Close | 0.2250 |
| Open | 0.2250 |
| Bid | 0.2250 x 0 |
| Ask | 0.2400 x 0 |
| Day's Range | 0.2250 - 0.2250 |
| 52 Week Range | 0.0800 - 0.5100 |
| Volume | 3,255 |
| Avg. Volume | 28,209 |
| Market Cap | 8.404M |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Advanced Proteome Therapeutics Technology Featured in Oral Presentation at the World Molecular Imaging Congress
Vancouver, British Columbia--(Newsfile Corp. - October 4, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), is pleased to announce that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI") will have its technology featured in an oral presentation at the World Molecular Imaging Congress.As previously announced, APTI and the Zeglis lab at the City University of New York, are pursuing a collaboration to investigate APTI's site-selective c
- Newsfile
Advanced Proteome Therapeutics Provides Update on COVID Program
Burnaby, British Columbia--(Newsfile Corp. - August 24, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company"), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.As previously announced, APTI's scientists identified multiple compounds with high predicted affinity for the main SARS-CoV-2 protease by in silico modeling and synthetic efforts and pre
- Newsfile
Advanced Proteome Therapeutics Announces Appointment of Dr. Benjamin Krantz to CEO
Burnaby, British Columbia--(Newsfile Corp. - July 21, 2021) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E8) ("APC" or the "Company") is pleased to announce that as previously planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI").Prior to this appointment, Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center and served on the Board of Directors
